Caris Life Sciences Presents Data Demonstrating the Ability of ADAPT Biotargeting System to Identify Responders and Non-Responders in a Phase III Pancreatic Cancer Study
Leveraging ADAPT Biotargeting System would have significantly increased the probability of success
Data presented at the ESMO World Congress on Gastrointestinal Cancer 2018
IRVING, Texas, June 21, 2018 -- (Healthcare Sales & Marketing Network) -- Ca... Diagnostics, Oncology Caris Life Sciences, ADAPT Biotargeting System, precision medicine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Gastroenterology | Marketing | Pancreas | Pancreatic Cancer | Pharmaceuticals | Politics | Study